Recently, Hualan Biological Engineering Co., Ltd. (referred to as ‘Hualan Bio’) announced its intention to acquire a 35% equity stake in Guangfeng Capsule Co., Ltd. using its own funds. This move aims to further expand Hualan Bio’s presence in the pharmaceutical excipients and capsule dosage form sectors, enhancing synergy across its supply chain. Guangfeng Capsule is one of China’s early entrants in the development and manufacturing of empty capsules, boasting mature production processes and a stable customer base. By acquiring this stake, Hualan Bio expects to integrate upstream critical excipient resources, strengthen self-reliance in drug manufacturing, and lay the groundwork for future development of novel drug delivery systems. Although Hualan Bio will not gain controlling interest in Guangfeng Capsule through this transaction, it will become a key strategic shareholder, enabling deeper collaboration in technology, production capacity, and market channels. This initiative also marks a significant step for Hualan Bio to diversify beyond its core biopharmaceutical business into the broader health industry and optimize its overall business structure. The deal is still subject to regulatory approvals and the execution of definitive agreements, and its completion remains uncertain.
近日，华兰生物工程股份有限公司（简称“华兰股份”）发布公告称，公司拟以自有资金受让广峰胶囊有限公司35%的股权。此次交易旨在进一步拓展公司在医药辅料及胶囊制剂领域的布局，增强产业链协同效应。广峰胶囊作为国内较早从事空心胶囊研发与生产的企业之一，拥有较为成熟的生产工艺和稳定的客户资源。通过本次股权受让，华兰股份有望整合上游关键辅料资源，提升药品生产的自主可控能力，并为未来开发新型给药系统奠定基础。交易完成后，华兰股份虽未实现对广峰胶囊的控股，但将成为其重要战略股东，双方将在技术、产能及市场渠道等方面展开深度合作。此举也被视为华兰股份在生物制药主业之外，积极布局大健康产业、优化业务结构的重要一步。目前，该交易尚需履行相关审批程序及签署正式协议，最终能否实施仍存在不确定性。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/11396.html